The Effect of Glucagon on Cerebral Glucose Metabolism in Healthy Humans

Summary

This is a pilot study in which the investigators will investigate the effect of exogenous glucagon on cerebral glucose metabolism in healthy humans.

Participants will participate in either part C or part D of the study, and each participant will participate in three study days. During a study day the participant will receive an intravenous infusion of either glucagon, glucose (in an adjustable rate to match to glucose concentrations achieved with the glucagon infusion) or saline. During each study day an 18F-flouro-deoxy-glucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) scan will be performed to quantify cerebral glucose metabolism during the first part (acute effect) of the glucagon/glucose/saline infusion (part C) or the last part (later effect) of the glucagon/glucose/saline infusion (part D).

Conditions

• Cerebral Glucose Metabolism

Interventions

OTHER

Glucagon (part C)

90 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).

OTHER

Glucose clamp (part C)

90 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).

OTHER

Saline (part C)

90 minutes intravenous infusion with isotonic NaCl.

OTHER

Glucagon (part D)

210 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).

OTHER

Glucose clamp (part D)

210 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).

OTHER

Saline (part D)

210 minutes intravenous infusion with isotonic NaCl.

Sponsors & Collaborators

• University Hospital Bispebjerg and Frederiksberg

  collaborator OTHER

• Nicolai Jacob Wewer Albrechtsen

  lead OTHER

Principal Investigators

• Nicolai J Wewer Albrecthsen, MD PhD · Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

• Lisbeth J Marner, MD PhD · University Hospital Bispebjerg and Frederiksberg

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

CROSSOVER

Eligibility

Min Age

55 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-03-18

Primary Completion

2026-05-31

Completion

2027-08-31

Countries

• Denmark

Study Locations